← Leaderboards
Peter Qinhua Huang
Kalyra Pharmaceuticals, Inc.
$998,134
Attributed
$1,996,267
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2018–19$2M$1.5M$1M$500K$0
'18
'19
Funding mix
By agency
NIH$1,996,267 · 1
By mechanism
R44$1,996,267 · 1
Top collaborators
- Ahmed Samatar3 shared
Most similar at Kalyra Pharmaceuticals, Inc.
Same institution · by research overlap
- Ahmed Samatar$1,146,911
Others in their field
Other Emerging Leaders on “In Vivo Model”
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
- John Damon Chodera · Sloan-Kettering Inst Can Research$43,427,103
- Alan D. Palkowitz · Indiana University Indianapolis$18,925,366
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$16,644,534
Research focus
In Vivo ModelMap Kinase GeneIncidenceIn VivoMalignant Neoplasm Of PancreasMap Kinase ActivatorExtracellularHandInhibitor/AntagonistIn VitroLeadCessation Of LifeMalignant NeoplasmsMapk3 GeneClinical TrialsBinding ProteinsDiagnosisCancer Cell LineDrug CandidateBioavailableEffective TherapyInterestKras2 GeneMeks
Grant awards (3)
Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$856,578
R44 · FY2019 · CA · contact PI
Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$1,060,799
R44 · FY2018 · CA · contact PI
Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$78,890
R44 · FY2018 · CA · contact PI